New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
09:09 EDTAGENAgenus announces 'promising' Prophage G-200 Phase 2 results
Agenus announced that Phase 2 results of Prophage G-200 vaccine in recurrent patients with glioblastoma multiforme were hailed as "exciting" and a "very promising therapy" in an editorial published in Neuro-Oncology. The results of Agenusí Prophage vaccine Phase 2 study, published last month in Neuro-Oncology, demonstrated that more than 90% of the patients treated with the vaccine candidate were alive at six months. The median overall survival in these patients was approximately 11 months. The results of the Phase 2 trial have garnered the support of the National Cancer Institute. The study is actively enrolling and will offer the opportunity to provide important data to validate assessments of biomarkers and imaging criteria.
News For AGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 1, 2015
16:55 EDTAGENAgenus files to sell 574,140 shares of common stock for holders
Subscribe for More Information
April 27, 2015
08:46 EDTAGENAgenus data positive, says JMP Securities
Subscribe for More Information
April 24, 2015
07:11 EDTAGENAgenus: GSK's RTS,S vaccine showed statistically significant results in study
Subscribe for More Information
April 23, 2015
07:03 EDTAGENAgenus reports Q1 EPS (28c), may not compare to consensus (1c)
Reports Q1 revenue $3.95M, may not compare to consensus $11.66M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use